Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

MDRNA to receive European patent for its intranasal insulin formulation

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the European Patent Office intends to grant a patent for application EP06826368 covering formulations for the intranasal delivery of rapid acting insulin, and its use for the treatment of diabetes.

21 Jan 2010

USPTO issues Notice of Allowance for IntelGenx's bupropion patent

IntelGenx Corp. ("IntelGenx") today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a formal Notice of Allowance for a key patent application protecting IntelGenx's CPI-300, a novel, high strength formulation of bupropion hydrochloride ("HCl"), the active ingredient in Wellbutrin XL(R).

21 Jan 2010

Quorum sensing offers a dynamic approach to increase sensitivity to external signals

Researchers at UC San Diego who last year genetically engineered bacteria to keep track of time by turning on and off fluorescent proteins within their cells have taken another step toward the construction of a programmable genetic sensor. The scientists recently synchronized these bacterial "genetic clocks" to blink in unison and engineered the bacterial genes to alter their blinking rates when environmental conditions change.

21 Jan 2010

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

pSivida Corp., a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22.

21 Jan 2010

Lupin's Mandideep facility receives FDA clearance

Pharma major, Lupin Ltd announced today that it has received official communication from the US FDA on the satisfactory resolution of the Warning Letter issued earlier to its Mandideep site. The company had received a Warning letter for its Mandideep site in May 2009. In the ensuing seven months, the company made significant enhancements and took appropriate corrective actions.

21 Jan 2010

Diamyd Medical executes share split

Diamyd Medical announces today that the company executes a 2:1 division of shares (i.e. a split), meaning that each share is divided into two shares of the same class.

20 Jan 2010

Access Pharmaceuticals provides update on its Cobalamin insulin development program

ACCESS PHARMACEUTICALS, INC. provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body's natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism.

20 Jan 2010

Depomed plans additional Serada Phase 3 trial for treatment of menopausal hot flashes

Depomed, Inc. announced today it has received guidance from the FDA in formal meeting minutes from a meeting held in December regarding SeradaTM, the company’s extended release gabapentin product candidate for the treatment of menopausal hot flashes. Based on guidance reflected in the meeting minutes, Depomed plans to conduct a single additional pivotal Phase 3 trial evaluating Serada for the treatment of menopausal hot flashes.

20 Jan 2010

JDRF and BD join to develop novel insulin delivery products for treatment of type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and BD (Becton, Dickinson and Company) announced today an innovative program aimed at improving the treatment of type 1 diabetes by developing novel insulin delivery products to enhance the use of insulin pumps.

From BD (Becton, Dickinson and Company) 20 Jan 2010

DURECT commences dosing in its POSIDUR Phase III clinical trial

DURECT Corporation announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR™ (SABER™-Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial, referred to as BESST (Bupivacaine Effectiveness and Safety in SABER Trial), is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in patients undergoing general surgical procedures.

19 Jan 2010

Accellent reports preliminary financial information for fiscal fourth-quarter ended December 31, 2009

Accellent Inc. (the “Company”), a wholly owned subsidiary of Accellent Holdings Corp. (“Accellent”), today announced certain preliminary financial information for its fiscal fourth quarter and the full year ended December 31, 2009.

19 Jan 2010

Accellent to refinance its existing senior secured credit facilities

Accellent Inc. announced today that it has adopted a plan to refinance (the "Refinancing") its existing senior secured credit facilities and replace them with indebtedness that has longer-dated maturities. The plan, which has been unanimously approved by the Company's Board of Directors, would strengthen the Company’s capital structure by extending nearer term maturities such that the Company has no maturities until November 2013.

19 Jan 2010

Dramatically enhanced image contrast could revolutionize diagnostics and therapeutics

A Northwestern University study shows that coupling a magnetic resonance imaging (MRI) contrast agent to a nanodiamond results in dramatically enhanced signal intensity and thus vivid image contrast.

18 Jan 2010

Protectus Medical Devices and Moll Industries sign manufacturing agreement

Protectus Medical Devices, Inc. ("Protectus Medical Devices"), a developer and marketer of innovative medical devices, today announced the signing of a three-year manufacturing agreement with Moll Industries, Inc. to provide injection molded plastic manufacturing services for the Protectus Safety Syringe.

17 Jan 2010

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.

13 Jan 2010

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug’s bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.

13 Jan 2010

BDSI to discuss planned BEMA Granisetron IND with the FDA

BioDelivery Sciences International, Inc. announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI’s antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.

13 Jan 2010

NitricBio chooses Clinipace Worldwide to manage and conduct two phase 3 trials

Clinipace Worldwide, a global technology-driven clinical research organization (CRO), announced today that NitricBio has selected the company to manage and deploy multiple studies in support of medical applications of topical nitric oxide gas (gNO).

13 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

A.P. Pharma regains compliance for continued listing on Nasdaq Capital Market

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1).

11 Jan 2010

Drug Delivery News and Research

Further Reading

MDRNA to receive European patent for its intranasal insulin formulation

USPTO issues Notice of Allowance for IntelGenx's bupropion patent

Quorum sensing offers a dynamic approach to increase sensitivity to external signals

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

Lupin's Mandideep facility receives FDA clearance

Diamyd Medical executes share split

Access Pharmaceuticals provides update on its Cobalamin insulin development program

Depomed plans additional Serada Phase 3 trial for treatment of menopausal hot flashes

JDRF and BD join to develop novel insulin delivery products for treatment of type 1 diabetes

DURECT commences dosing in its POSIDUR Phase III clinical trial

Accellent reports preliminary financial information for fiscal fourth-quarter ended December 31, 2009

Accellent to refinance its existing senior secured credit facilities

Dramatically enhanced image contrast could revolutionize diagnostics and therapeutics

Protectus Medical Devices and Moll Industries sign manufacturing agreement

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

BDSI to discuss planned BEMA Granisetron IND with the FDA

NitricBio chooses Clinipace Worldwide to manage and conduct two phase 3 trials

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

A.P. Pharma regains compliance for continued listing on Nasdaq Capital Market

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News